CryoPort, Inc. (NASDAQ:CYRX) Receives $12.83 Average PT from Analysts

CryoPort, Inc. (NASDAQ:CYRX) has been assigned an average rating of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $12.8333.

Several equities research analysts have recently issued reports on CYRX shares. Needham & Company LLC raised their target price on CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. UBS Group increased their price target on shares of CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a research report on Monday, December 29th.

CryoPort Price Performance

CryoPort stock opened at $8.60 on Friday. CryoPort has a 52 week low of $4.58 and a 52 week high of $11.45. The company’s 50 day moving average price is $9.90 and its two-hundred day moving average price is $9.31. The stock has a market cap of $430.60 million, a P/E ratio of 7.35 and a beta of 1.66. The company has a quick ratio of 15.01, a current ratio of 15.77 and a debt-to-equity ratio of 0.40.

CryoPort (NASDAQ:CYRX) last released its earnings results on Tuesday, November 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. The company had revenue of $44.23 million during the quarter, compared to analyst estimates of $41.22 million. CryoPort had a negative return on equity of 11.07% and a net margin of 35.57%. On average, equities analysts predict that CryoPort will post -0.99 earnings per share for the current year.

Insider Activity at CryoPort

In related news, Director Ramkumar Mandalam sold 11,570 shares of CryoPort stock in a transaction that occurred on Wednesday, December 10th. The shares were sold at an average price of $9.99, for a total value of $115,584.30. Following the sale, the director owned 80,758 shares of the company’s stock, valued at approximately $806,772.42. The trade was a 12.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 10.00% of the company’s stock.

Institutional Trading of CryoPort

A number of large investors have recently bought and sold shares of the company. AQR Capital Management LLC lifted its position in shares of CryoPort by 285.5% during the 1st quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock valued at $1,597,000 after buying an additional 194,482 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in CryoPort in the 2nd quarter worth about $123,000. CWM LLC raised its stake in CryoPort by 56.2% in the 2nd quarter. CWM LLC now owns 17,697 shares of the company’s stock valued at $132,000 after acquiring an additional 6,369 shares during the period. Conestoga Capital Advisors LLC lifted its holdings in CryoPort by 55.9% during the second quarter. Conestoga Capital Advisors LLC now owns 110,557 shares of the company’s stock valued at $825,000 after purchasing an additional 39,640 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in CryoPort by 299.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company’s stock valued at $27,000 after purchasing an additional 2,729 shares during the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.